News - Vivalis, Analgesia

Filter

Current filters:

VivalisAnalgesia

Popular Filters

Executive Q&A: Bob Radie, chief executive and president of Egalet

Executive Q&A: Bob Radie, chief executive and president of Egalet

11-04-2014

In an interview with The Pharma Letter, Egalet Corporation’s chief executive Bob Radie discusses the…

AnalgesiaChemistryChief executiveCombination productsEgalet CorpEgalet CorporationInterviewsPharmaceuticalSevere chronic painUSA

Study: Half of veterans prescribed medical opioids continue to use them chronically

Study: Half of veterans prescribed medical opioids continue to use them chronically

07-03-2014

A study of nearly 1 million veterans who receive opioids to treat painful conditions found that more…

AnalgesiaHealthcarePharmaceuticalResearchUSA

FDA says Durect’s pain relief drug Posidur needs additional safety studies

FDA says Durect’s pain relief drug Posidur needs additional safety studies

13-02-2014

US drugmaker Durect Corp says that the US Food and Drug Administration has issued a Complete Response…

AnalgesiaDurectPharmaceuticalPosidurRegulationUSA

Altus signs $4 million agreement with Zogenix to license Zohydro ER

04-11-2013

Altus Pharmaceuticals has entered into an agreement with Zogenix to develop abuse deterrent formulations…

AnalgesiaLicensingNorth AmericaPharmaceuticalZogenixZohydro

Orexo’s Zubsolv could take market share from Suboxone, report suggests

Orexo’s Zubsolv could take market share from Suboxone, report suggests

30-10-2013

Edison Equity Research analysts say that expected new clinical data from Swedish drug developer Orexo…

AnalgesiaFinancialMarkets & MarketingNorth AmericaOrexo ABPharmaceuticalReckitt BenckiserZubsolv

Zogenix shares leap after FDA approval for Zohydro ER

Zogenix shares leap after FDA approval for Zohydro ER

28-10-2013

Shares of Zogenix rocketed on Friday after the US Food and Drug Administration approved Zohydro ER extended-release…

AnalgesiaNorth AmericaPharmaceuticalRegulationZogenixZohydro

FDA calls for reclassification of codeine combo medications to stricter schedules

FDA calls for reclassification of codeine combo medications to stricter schedules

25-10-2013

The US Food and Drug Administration has indicated that it wants to see the classification of codeine-containing…

AnalgesiaHydrocodone Bitartrate and AcetaminophenNorth AmericaPharmaceuticalRegulation

Pfizer to continue Remoxy pain relief development

Pfizer to continue Remoxy pain relief development

24-10-2013

US pharma giant Pfizer will continue the development program for Remoxy Extended-Release Capsules CII,…

AnalgesiaNorth AmericaPfizerPharmaceuticalRemoxyResearch

Iroko’s pain relief drug effective at low doses

Iroko’s pain relief drug effective at low doses

22-10-2013

Iroko Pharmaceuticals has announced that the US Food and Drug Administration has approved Zorvolex capsules…

AnalgesiaIrokoNorth AmericaPharmaceuticalRegulationZorvolex

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

Mixed results for Pfizer’s two Lyrica Phase IIIb studies

21-10-2013

Pfizer has announced mixed results from two Phase IIIb studies of Lyrica capsules CV in patients with…

AnalgesiaLyricaNorth AmericaPfizerPharmaceuticalResearch

UK’s medicines watchdog recalls five Wockhardt medicines

UK’s medicines watchdog recalls five Wockhardt medicines

18-10-2013

The UK’s Medicines and Healthcare products Regulatory Agency has recalled five medicines made by Indian…

AnalgesiaDiabetesEuropeGliclazidePharmaceuticalProductionRegulationWockhardt

Merger between Intercell and Vivalis planned to complete soon

14-05-2013

French biotech firm Vivalis (Euronext: VLS) previously-announced acquisition of Intercell (ICEL.VI) in…

BiotechnologyIntercellMergers & AcquisitionsVaccinesValnevaVivalis

Vivalis and Intercell announce "merger of equals"

18-12-2012

French biotech firm Vivalis (Euronext: VLS) has entered into an accord to acquire Intercell (ICEL.VI)…

BiotechnologyIntercellMergers & AcquisitionsVaccinesValnevaVivalis

Vivalis in new EB66 cell line deal with Merial

18-07-2012

France-based Vivalis (NYSE Euronext: VLS) announced today that it has executed a new research license…

EB66LicensingMerialPharmaceuticalSanofiVaccinesVivalis

Vivalis signs another EB66 out-licensing deal for MAb production

14-03-2012

French biotech firm Vivalis (NYSE Euronext: VLS) has signed a joint collaboration and commercial license…

BiotechnologyEB66LicensingVaccinesVivalis

Vivalis opens new lab for antibody discovery; posts 112% revenue hike

25-01-2012

French biotech firm Vivalis (NNYSE Euronext: VLS) says it has opened a new facility for partnered VIVA|Screen…

BiotechnologyEuropeFinancialResearchSanofi PasteurVivalis

Sanofi Pasteur and Vivalis extend MAb accord

19-01-2012

French biopharma company Vivalis (NYSE Euronext: VLS) says it has extended the agreement signed in 2010…

Antibiotics and Infectious diseasesLicensingPharmaceuticalResearchSanofiSanofi PasteurVivalis

Strong first-half 2011 for Vivalis, with net loss nearly halved

01-09-2011

French biotech firm Vivalis (Euronext Paris: VLS) has released its audited consolidated results for the…

BiotechnologyFinancialVivalis

Vivalis acquires single-cell antibody from SC World

28-04-2011

French drug firm Vivalis (Euronext: VLS) says it has acquired high-throughput screening (HTS) single-cell…

Asia-PacificLicensingPharmaceuticalSC WorldVivalis

Kaketsuken initiates second trial of flu vaccine using Vivalis EB66 cell line

26-04-2011

Japan’s Chemo-Sero-Therapeutic Research Institute (Kaketsuken) has initiated the first human injection…

GlaxoSmithKlineKaketsukenPharmaceuticalResearchRespiratory and PulmonaryVaccinesVivalis

Back to top